 |
|
A Double-blind, Placebo-Controlled Study of Oral Nalmefene for Alcohol Dependence
Barbara J. Mason, PhD;
Fernando R. Salvato, MD;
Lauren D. Williams, MD;
Eva C. Ritvo, MD;
Robert B. Cutler, PhD
Arch Gen Psychiatry. 1999;56:719-724.
Background Nalmefene is a newer opioid antagonist that is structurally similar to naltrexone but with a number of potential pharmacological advantages for the treatment of alcohol dependence, including no dose-dependent association with toxic effects to the liver, greater oral bioavailability, longer duration of antagonist action, and more competitive binding with opioid receptor subtypes that are thought to reinforce drinking.
Methods A double-blind, placebo-controlled trial was conducted to evaluate the safety and efficacy of 2 doses of oral nalmefene for alcohol dependence. The 105 outpatient volunteers were abstinent for a mean of 2 weeks prior to random assignment to the placebo or 20- or 80-mg/d dose nalmefene groups for 12 weeks. Cognitive behavioral therapy was provided weekly during treatment. Self-reported drinking or abstinence was confirmed by determinations of breath alcohol concentration and by collateral informant reports.
Results Outcomes did not differ between the 20- and 80-mg dose nalmefene groups. Significantly fewer patients treated with nalmefene than patients given placebo relapsed to heavy drinking through 12 weeks of treatment (P<.02), with a significant treatment effect at the first weekly study visit (P<.02). The odds ratio of relapsing to heavy drinking was 2.4 times greater with placebo compared with nalmefene (95% confidence interval, 1.05-5.59). Patients treated with nalmefene also had fewer subsequent relapses (P<.03) than patients given placebo.
Conclusions Treatment with nalmefene was effective in preventing relapse to heavy drinking relative to placebo in alcohol-dependent outpatients and was accompanied by acceptable side effects.
From the Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami, Fla.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Multicenter Investigation of the Opioid Antagonist Nalmefene in the Treatment of Pathological Gambling
Grant et al.
Am. J. Psychiatry 2006;163:303-312.
ABSTRACT
| FULL TEXT
Initial and Maintenance Naltrexone Treatment for Alcohol Dependence Using Primary Care vs Specialty Care: A Nested Sequence of 3 Randomized Trials
O'Malley et al.
Arch Intern Med 2003;163:1695-1704.
ABSTRACT
| FULL TEXT
Naltrexone Treatment for Alcohol Dependence
Fuller and Gordis
NEJM 2001;345:1770-1771.
FULL TEXT
Alcoholism Treatment After Liver Transplantation: Lessons Learned From a Clinical Trial That Failed
Weinrieb et al.
Psychosomatics 2001;42:110-116.
ABSTRACT
| FULL TEXT
Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism
Sinclair
Alcohol Alcohol 2001;36:2-10.
ABSTRACT
| FULL TEXT
PHARMACOTHERAPY OF ALCOHOLISM: GAPS IN KNOWLEDGE AND OPPORTUNITIES FOR RESEARCH
Kranzler
Alcohol Alcohol 2000;35:537-547.
ABSTRACT
| FULL TEXT
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF NALTREXONE IN THE TREATMENT OF ALCOHOL DEPENDENCE OR ABUSE
Chick et al.
Alcohol Alcohol 2000;35:587-593.
ABSTRACT
| FULL TEXT
Naltrexone plus cognitive behavioural therapy led to fewer drinking relapses in outpatients with alcoholism
Chick
Evid. Based Ment. Health 2000;3:75-75.
FULL TEXT
Oral nalmefene reduced relapse to heavy drinking and was well tolerated in patients with alcohol dependence
Chick
Evid. Based Ment. Health 2000;3:20-20.
FULL TEXT
Opiate Antagonist Helps Prevent Alcoholism Relapse
JWatch Psychiatry 1999;1999:17-17.
FULL TEXT
Opiate Antagonist Helps Prevent Alcoholism Relapse
JWatch General 1999;1999:4-4.
FULL TEXT
|
